Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Regulatory Routine +

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

By The Northwire Desk — AI Analysis Apr 02, 2026 · 08:30 QNTM · 6.16 Quantum BioPharma Ltd.
QNTM · Price

Executive Summary

  • A U.S. District Court in the Southern District of New York issued a ruling largely rejecting CIBC World Markets’ and RBC Dominion Securities’ joint motion to dismiss Quantum BioPharma’s lawsuit alleging illegal market manipulation.
  • The lawsuit claims that between Jan 1 2020 and Aug 15 2024 the defendants engaged in “spoofing” to manipulate Quantum BioPharma’s share price, violating Sections 10(b), 9(a) and Rule 10b‑5 of the Securities Exchange Act of 1934.
  • The court’s decision represents a significant step forward for Quantum BioPharma’s legal claim and may have material implications for the company’s shareholders and future litigation strategy.

Key Details

  • Court Ruling: United States District Court for the Southern District of New York largely denied CIBC World Markets (“CIBC”) and RBC Dominion Securities (“RBC”) joint motion to dismiss the lawsuit.
  • Allegations: Quantum BioPharma alleges that from 1 Jan 2020 to 15 Aug 2024 the defendants or their customers used “spoofing” techniques to manipulate the company’s share price, violating Section 10(b) and Rule 10b‑5(a)/(c), as well as Section 9(a) of the Securities Exchange Act of 1934.
  • Legal Significance: The ruling allows Quantum BioPharma’s claims to proceed, potentially leading to discovery, further motions, or settlement negotiations.
  • Full Court Opinion: Available via the provided link – “District Court Opinion & Order.”

Notable Quotes

(No direct quotes were included in the release.)

Read the original news release →

More from Quantum BioPharma Ltd.

Jun 26, 2026 · 08:30

Preclinical MS drug developer navigating FDA clinical hold while leveraging consumer supplement royalties.

Other Jun 25, 2026 · 08:30

Pre-revenue MS developer navigates FDA clinical hold while doubling down on myelin-repair narrative and consumer-health royalties

Other Jun 24, 2026 · 08:30

A pre-revenue biotech touting an MS drug's potential while its lead IND sits on clinical hold and the company stays silent on the setback in its latest marketing push.

Other Jun 22, 2026 · 08:30

Pre-revenue MS drug developer navigating FDA hold and negative equity while pursuing a $700M manipulation lawsuit.

Other Jun 01, 2026 · 19:30

A clinical hold on its lead MS drug and the sudden exit of a key director deal a double blow to Quantum BioPharma, erasing near-term catalysts and raising red flags about governance and data quality.

Regulatory May 18, 2026 · 03:00

Quantum BioPharma’s MS study hits halfway mark with early positive imaging signals, but the real catalyst remains an imminent FDA greenlight for its Phase 2 trial.

Other